It was first developed in 1991 as a derivative of Body Protection Compound, a peptide naturally found in human gastric juices [1, 2]
In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
Bioavailability of oral formulations is typically 1-3% compared to near 100% for subcutaneous injection
Comparison between Serum Holotranscobalamin and Total Vitamin B12 as Indicators of Vitamin B12 Status
These three use cases reflect different biological contexts and different expected time horizons for response
These compounds work by mimicking hormones that regulate appetite and glucose metabolism, producing significant weight loss primarily through reduced food intake
